Sylvain Fanier, Msc. EMBA

President

Entrepreneur with more than 30 years of experience (JNJ, BARD, LEMERPAX, CARDIOINSIGHT, SONOSCANNER, MED-INNOV…). Sylvain has led several breakthrough medical innovations from concept to global commercialization.

Nicolas Cherrier, PharmD.

Managing Director

Pharmacist with a background in management (ISG and Henley Business School) Nicolas devoted himself for several years to the analytical and pharmacotechnical development of renowned specialties within an international pharma group, which allowed him to acquire a solid “pharmaceutical culture”, and to master all the technical and regulatory aspects of research and development.

This first experience was followed by the management of a regional management in Africa within a “Big Pharma”, an exciting experience marked by the successful launch of major specialties, the implementation of the various tools of “pharma marketing” and the discovery of the realities and riches of multicultural management.

His mastery of the “market developer” function was then refined during 25 years in companies specializing in nuclear medicine as export zone manager, subsidiary director, and international network director.

The valorization of his experience and a certain number of assets (dynamism, enthusiasm, initiative, entrepreneur, creative, “team-player “) led him to take up a new challenge through the creation at the end of 2017 of Equinoxe Pharma, a consulting company whose DNA is to support companies specializing in nuclear medicine, molecular imaging and contrast media in their international development plans and projects.

In June 2021, Nicolas joined Naogen Pharma as Director of Business Development, then was appointed in May 2022 Chief Executive Officer with the missions of successfully completing the MA submission project, and managing the pre-marketing activities of our Rubidium-82 generator.

Jean-François Chatal, MD, PhD

Co-Founder, Chief Medical Officer

Pioneer in nuclear medicine, former head of nuclear medicine at the University Hospital and Cancer Center of Nantes, Professor Emeritus of Nuclear Medicine at the University of Nantes, Director of a research laboratory in oncology and immunology; founded ATLAB in 2008, sold to TELIX in 2018.

Catherine Barde-de Ponthaud

Sales and Marketing Director

Catherine began her career at Cisbio International/Curium, where she held various sales and marketing positions and acquired in-depth knowledge of SPECT and PET radiopharmaceuticals. 

In 2014, Catherine moved to London where she continued her career with Blue Earth Diagnostics to manage the launch of new radiopharmaceuticals in oncology and cardiology on the French and European market. 

Since January 2023, Catherine has joined the Naogen Pharma team as Sales and Marketing Director where she will be in charge of the commercialization of the Rubidium 82 generator.

Sébastien Avila, PhD Eng.

Co-Founder, Chief Technical Officer

Expert in R&D and industrial development of nuclear medicine technologies and radiopharmaceutical solutions.

Patrick Breau, PharmD.

Chief Reg. Affairs – Head Pharmacist

More than 17 years of experience in the pharmaceutical industry in France and Africa for international laboratories. His career has spanned all stages of a drug’s life cycle, from R&D for IPSEN, to production and packaging for SANOFI, as well as distribution/commercialization for a Novartis generic subsidiary.

Justine Bayle, PharmD.

Head of production

Doctor of Pharmacy, Justine began her career in the sterile production of injectable drugs at MSD. She then joined Cyclopharma (future Curium), where she gained experience in the sterile production of fluorine-18, as assistant pharmacist and then site manager and deputy pharmacist. His PCR (Person Competent in Radiation Protection) diploma consolidated his knowledge in the field of radioactivity.

She then joined Naogen Pharma as Production Manager, to bring her experience in the industrial production of radiopharmaceutical drugs.

Franck Moinard, KEDGE Business School (2001)

Chief Financial Officer

Franck began his career in Paris in 2001 in financial audit (Mazars) before holding senior positions in financial control at BNP Paribas and then within the AGF group, where he supported the transformation into ALLIANZ France. With these experiences, Franck then joined PWC where he specialized in financial management and structuring of the Finance function.

In 2013, Franck left Paris for Nantes where he took responsibility for the financial control of KEREIS, a group under LBO, whose strong development (scale-up) is based on international development and a build-up strategy. After 6 years in the KEREIS group, which he saw double in size, Franck joined the pharmaceutical sector by joining the Atlanta group (2 CROs and 1 biotech) as CFO. He supports the Herblinois group in its development by structuring the Finance function and contributing to the setting up of various financing operations (fundraising, recovery plan grants, PGE, etc.).